Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA7 | P43166 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | LATS1 | O95835 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20659338 | 0.98 | TDP1 (0.38) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL21261831 | 0.89 | TDP1 (0.42) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL3615746 | 0.86 | APLNR (0.39) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL1437011 | 0.85 | TDP1 (0.40) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL19967421 | 0.84 | CA1 (0.33) | TDP1CA1CA2CA7MAOA | |
| Hydrochloric Acid SCHEMBL28622640 | 0.83 | TDP1 (0.39) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL1359163 | 0.83 | TDP1 (0.47) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL11966911 | 0.83 | ALDH1A1 (0.52) | TDP1CA1CA2CA7MEN1 | |
| SCHEMBL2942997 | 0.82 | TDP1 (0.38) | TDP1CA1CA2CA7MAOA | |
| SCHEMBL26103826 | 0.82 | TDP1 (0.42) | TDP1CA1CA2CA7MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109732-A1 | LIPID AMINES | MODERNATX INC (US) | 2026-04-23 | — | — | US | disclosed |
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MODERNATX, INC. (US) | 2025-07-24 | — | — | US | disclosed |
| EP-4475882-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | ModernaTX, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| EP-4423107-A1 | LIPID AMINES | ModernaTX, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| CN-116768885-A | N 2 -substituted bicyclo-2-aminopyrimidine derivative, preparation method and medical application thereof | 浙江大学 | 2023-09-19 | — | — | CN | disclosed |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | NOVARTIS INSTITUTE FOR FUNTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2023-06-22 | — | — | US | disclosed |
| WO-2023076598-A1 | LIPID AMINES | MODERNATX, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| CN-115996929-A | Antagonists of adenosine A2a receptors | 阿道尔克斯治疗有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-4146654-A1 | ANTAGONISTS OF THE ADENOSINE A2A RECEPTOR | Adorx therapeutics Limited (GB) | 2023-03-15 | — | — | EP | disclosed |
| EP-2432779-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | Exelixis, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2011128279-A1 | ARYLETHYNYL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251169-A1 | Arylethynyl derivatives | HOFFMANN-LA ROCHE, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| WO-2010135524-A1 | BENZOXAZEPINES BASED P13K/MT0R INHIBITORS AGAINST PROLIFERATIVE DISEASES | EXELIXIS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-01 | — | — | US | disclosed |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-17 | — | — | US | disclosed |
| WO-2007048842-A1 | BENZIMIDAZOLE DERIVATIVES FOR USE AS BETA-3 RECEPTOR AGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103138-A1 | Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions | ADRB1, ADRB3, ADRB2 | TDP1 1405/4885CA1 1998/4885CA2 1043/4885 |
| US-20100298290-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | TDP1 4064/4885CA1 1348/4885CA2 428/4885 |
| US-20250235531-A1 | MUCOSAL ADMINISTRATION METHODS AND FORMULATIONS | MUC1, RNMT, FABP2 | TDP1 3192/4885CA1 4350/4885CA2 4557/4885 |
| US-20230190751-A1 | 6-6 Fused Bicyclic Heteroaryl Compounds and their Use as LATS Inhibitors | LATS1, LATS2, LSS | TDP1 2618/4885CA1 3631/4885CA2 1005/4885 |
| US-20110251169-A1 | Arylethynyl derivatives | GRM5, GRM1, GRM3 | TDP1 4160/4885CA1 4244/4885CA2 2032/4885 |
| US-20260109732-A1 | LIPID AMINES | LDLR, NPC1, PHOSPHO1 | TDP1 3880/4885CA1 1889/4885CA2 3992/4885 |
| US-20070112033-A1 | N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance | ADRB3, ADRB1, ADRA1B | TDP1 2029/4885CA1 4286/4885CA2 2275/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | TDP1 4286/4885CA1 3825/4885CA2 3956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.